Immune recovery following switch from EFV-based regimens to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed immunological non-responders: a 144-week real-world cohort study in China

1

The study identified a 29.9% prevalence of immunological non-responders (INRs) among people living with HIV on long-term antiretroviral therapy in Chongqing, China.
2

Switching from an efavirenz-based regimen to bictegravir/emtricitabine/tenofovir alafenamide significantly improved CD4 cell counts in INRs at 48, 96, and 144 weeks.
3

Immune reconstitution rates were higher in the BIC/FTC/TAF group compared to the EFV group at both week 48 and week 144.
4

The immunological benefits of switching therapy were primarily observed in patients aged 50 years or younger.
5

Virological suppression rates remained high in both the EFV and BIC/FTC/TAF groups throughout the study.

1